Quanterix Corp

Quanterix Corporation (NASDAQ: QTRX) is a life sciences company that develops and commercializes ultra-sensitive protein detection technologies for biomarker research, drug development, and clinical diagnostics. The company's website is www.quanterix.com.

The company operates through two primary technology platforms. Its Simoa technology enables detection of protein biomarkers at ultra-low concentrations in blood and other fluids through digital immunoassay methods, achieving sensitivity in the femtomolar range compared to conventional technologies. Simoa includes both bead-based instruments such as the HD-X and SR-X, and planar array instruments including the SP-X. The company's Spatial Biology platform, significantly expanded through the July 2025 acquisition of Akoya Biosciences, measures protein expression and cellular phenotypes within intact tissue while preserving spatial context, utilizing instruments such as the PhenoCycler, PhenoImager Fusion, and PhenoImager HT.

Quanterix generates revenue from three primary sources: instrument sales, consumables including approximately 65 assay kits for bead-based platforms and 45 for planar array platforms, and services through its CLIA-certified Accelerator Laboratory in Bedford, Massachusetts. The company offers four Laboratory Developed Tests through its Lucent Diagnostics service, including tests for Alzheimer's disease biomarkers and neurofilament light chain. Following the Akoya acquisition, revenue composition shifted from approximately 90 percent neurology to a diversified mix of roughly 60 percent neurology and 40 percent oncology.

The company maintains an installed base exceeding 2,500 instruments with scientific validation demonstrated through citations in more than 6,200 publications. Quanterix serves research laboratories, contract research organizations, academic institutions, and biopharmaceutical companies globally through direct sales in North America and Europe and through distributors in additional countries including China, Japan, India, and Australia. The company also acquired Emission, Inc. in January 2025 to secure manufacturing capabilities for proprietary magnetic beads used in next-generation platforms. As of February 2026, the company employed approximately 151 personnel in sales, marketing, and support functions, with additional staff across research, manufacturing, and administrative operations.